Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS–SWITCH analysis
Dangas GD, Mehran R, Nikolsky E et al.; HORIZONS-AMI Trial Investigators.
J Am Coll Cardiol 2011;57:2309–16.
Editor’s note: In this analysis of HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [MI]) trial data, the authors examined the outcomes of switching from heparin to bivalirudin treatment in patients with ST-segment elevation MI (STEMI) who had received heparin prior to angiography. Consistent with the results of the main trial, the results of this analysis showed that bivalirudin is associated with a lower rate of bleeding events, and also lower rates of short- and long-term cardiac-related mortality. Thus, antithrombin switching appears to be a viable and safe option for STEMI patients who have previously been treated with heparin.
» Read an expert review of this paper